These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 10160489)

  • 61. Non-traditional settings for influenza vaccination of adults: costs and cost effectiveness.
    Prosser LA; O'Brien MA; Molinari NA; Hohman KH; Nichol KL; Messonnier ML; Lieu TA
    Pharmacoeconomics; 2008; 26(2):163-78. PubMed ID: 18198935
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines.
    Nichol KL
    Vaccine; 2003 May; 21(16):1769-75. PubMed ID: 12686092
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cost-effectiveness of influenza vaccination in working-age cancer patients.
    Avritscher EB; Cooksley CD; Geraci JM; Bekele BN; Cantor SB; Rolston KV; Elting LS
    Cancer; 2007 Jun; 109(11):2357-64. PubMed ID: 17457827
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [An economic evaluation of strategy for expanding influenza vaccination in Japan].
    Hara Y
    Nihon Rinsho; 2003 Nov; 61(11):2013-8. PubMed ID: 14619447
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cost-effectiveness analysis of influenza vaccination for people aged 65 and over in Japan.
    Hoshi SL; Kondo M; Honda Y; Okubo I
    Vaccine; 2007 Aug; 25(35):6511-21. PubMed ID: 17681651
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Vaccination of healthy children against seasonal influenza: a European perspective.
    Heikkinen T; Tsolia M; Finn A
    Pediatr Infect Dis J; 2013 Aug; 32(8):881-8. PubMed ID: 23856713
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cost-effectiveness of childhood influenza vaccination in England and Wales: Results from a dynamic transmission model.
    Pitman RJ; Nagy LD; Sculpher MJ
    Vaccine; 2013 Jan; 31(6):927-42. PubMed ID: 23246550
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Economic evaluation of influenza vaccination and economic modelling. Can results be pooled?
    Jefferson T; Demicheli V
    Pharmacoeconomics; 1996; 9 Suppl 3():67-72. PubMed ID: 10160490
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cost-effectiveness of high-dose versus standard-dose inactivated influenza vaccine in adults aged 65 years and older: an economic evaluation of data from a randomised controlled trial.
    Chit A; Becker DL; DiazGranados CA; Maschio M; Yau E; Drummond M
    Lancet Infect Dis; 2015 Dec; 15(12):1459-66. PubMed ID: 26362172
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Economic evaluations of influenza vaccination in healthy working-age adults. Employer and society perspective.
    Wood SC; Nguyen VH; Schmidt C
    Pharmacoeconomics; 2000 Aug; 18(2):173-83. PubMed ID: 11067651
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Economic evaluation of influenza vaccination and economic modelling.
    Malek M
    Pharmacoeconomics; 1996; 9 Suppl 3():73-4. PubMed ID: 10160491
    [No Abstract]   [Full Text] [Related]  

  • 72. [Efficiency of influenza vaccination in the working population in Spain].
    de Juanes JR; Cisterna R; Sanz J; Magaz S; Badia X
    Gac Sanit; 2006; 20(2):101-7. PubMed ID: 16753086
    [TBL] [Abstract][Full Text] [Related]  

  • 73. WHO guide on the economic evaluation of influenza vaccination.
    Newall AT; Chaiyakunapruk N; Lambach P; Hutubessy RCW
    Influenza Other Respir Viruses; 2018 Mar; 12(2):211-219. PubMed ID: 29024434
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cost effectiveness of influenza vaccination in older adults: a critical review of economic evaluations for the 50- to 64-year age group.
    Newall AT; Kelly H; Harsley S; Scuffham PA
    Pharmacoeconomics; 2009; 27(6):439-50. PubMed ID: 19640008
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Health and economic burden of influenza-associated illness in South Africa, 2013-2015.
    Tempia S; Moyes J; Cohen AL; Walaza S; Edoka I; McMorrow ML; Treurnicht FK; Hellferscee O; Wolter N; von Gottberg A; Nguweneza A; McAnerney JM; Dawood H; Variava E; Cohen C
    Influenza Other Respir Viruses; 2019 Sep; 13(5):484-495. PubMed ID: 31187609
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Economics of employer-sponsored workplace vaccination to prevent pandemic and seasonal influenza.
    Lee BY; Bailey RR; Wiringa AE; Afriyie A; Wateska AR; Smith KJ; Zimmerman RK
    Vaccine; 2010 Aug; 28(37):5952-9. PubMed ID: 20620168
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cost-benefit evaluation of influenza vaccination in the elderly in the Italian region of Liguria.
    Gasparini R; Lucioni C; Lai P; Maggioni P; Sticchi L; Durando P; Morelli P; Comino I; Calderisi S; Crovari P
    Vaccine; 2002 Dec; 20 Suppl 5():B50-4. PubMed ID: 12477420
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Review of cost-benefit analyses of influenza vaccine.
    Perez-Tirse J; Gross PA
    Pharmacoeconomics; 1992 Sep; 2(3):198-206. PubMed ID: 10147010
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Correspondence to: Estimating the full health and economic benefits of current and future influenza vaccines.
    Waterlow NR; Procter SR; Eggo RM; Jit M
    BMC Med; 2023 Aug; 21(1):301. PubMed ID: 37559086
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cost effectiveness of influenza vaccination for healthy persons between ages 65 and 74 years.
    Nichol KL; Goodman M
    Vaccine; 2002 May; 20 Suppl 2():S21-4. PubMed ID: 12110251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.